Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-320

Even though the market responded positive to the news it’s well below where it was before they announced the failed primary endpoint. It’s clear to me that if they had used mortality as the primary endpoint the trial would’ve been described as massively successful and the price north of $6-7 . If one has a product that has been shown to reduce mortality from heart attacks you have a product for life. Look at the size of the Statens market and you get some idea of the potential here. With a market dominated by chronic short sellers there is potential for very big gains as this ( hopefully) approval process plays out. How long it takes will depend on what actions the FDA will require to make it approveable and how long that will take.